lenalidomide + OVA + CaCO3 dendritic cell vaccine

The **lenalidomide + OVA + CaCO3 dendritic cell vaccine** (also referred to as **LOC-DCs**) is an experimental immunotherapy that utilizes the **PROTAC** (proteolysis-targeting chimera) principle to enhance the efficacy of dendritic cell (DC) vaccines. The vaccine consists of dendritic cells pulsed with chimeric nanoantigens (LOC) composed of **lenalidomide** (a small molecular ligand for the E3 ubiquitin ligase **Cereblon**), **ovalbumin** (OVA, a model protein antigen), and **calcium carbonate** (CaCO3) nanoparticles. The CaCO3 nanoparticles facilitate the endosomal escape of the antigen into the DC cytosol. Once in the cytosol, the lenalidomide component recruits the E3 ligase to the OVA antigen, promoting its ubiquitination and subsequent degradation by the ubiquitin-proteasome system. This targeted degradation significantly accelerates MHC class I-associated cross-presentation (XPT), leading to the robust activation of tumor-specific cytotoxic T lymphocytes (CTLs). Mechanistically, this approach overcomes common limitations in the tumor microenvironment that typically compromise DC function.

Other names

lenalidomide-OVA-CaCO3 dendritic cell vaccinelenalidomide-OVA-CaCO-3 dendritic cell vaccinelenalidomide-OVA-CaCO 3 dendritic cell vaccinePROTAC-based nanoantigen DC vaccine